CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
University of Texas Southwestern Medical Center
Wake Forest University Health Sciences
Thomas Jefferson University
Wake Forest University Health Sciences
BeOne Medicines
M.D. Anderson Cancer Center
Lyell Immunopharma, Inc.
Children's Hospital of Philadelphia
Ohio State University Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Roswell Park Cancer Institute
National Institutes of Health Clinical Center (CC)
AIDS Malignancy Consortium
Canadian Cancer Trials Group
Innate Pharma
Bristol-Myers Squibb
Verismo Therapeutics
Incyte Corporation
Center for International Blood and Marrow Transplant Research
Wake Forest University Health Sciences
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
Merck Sharp & Dohme LLC
Genmab
Janssen Research & Development, LLC
Janssen Research & Development, LLC
National Cancer Institute (NCI)
Grifols Therapeutics LLC
Janssen Research & Development, LLC
Baylor College of Medicine
Genmab
Janssen Research & Development, LLC
Janssen Research & Development, LLC
University of Pittsburgh
Janssen Research & Development, LLC
Dana-Farber Cancer Institute
TCRx Therapeutics Co.Ltd
Janssen Research & Development, LLC
University of Miami
Conjupro Biotherapeutics, Inc.
Adicet Therapeutics
Washington University School of Medicine
Merck Sharp & Dohme LLC